{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:36:46Z","timestamp":1745469406660,"version":"3.40.4"},"reference-count":23,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Princ Pract"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>&lt;i&gt;Objective:&lt;\/i&gt; In this study, our aim was to evaluate the effect of a higher dose of atorvastatin on the recurrence rate of atrial fibrillation (AF) after electrical cardioversion (EC) in addition to antiarrhythmic therapy. &lt;i&gt;Subjects and Methods:&lt;\/i&gt; 48 patients with persistent AF were included in this study. The patients were randomized to an atorvastatin 40-mg treatment group and a control group. Atorvastatin was started 3 weeks before EC and was continued for 2 months after EC. EC was performed using biphasic shocks after 3 weeks of treatment with the orally administered anticoagulant warfarin. Lipid and inflammatory parameters (high-sensitivity C-reactive protein, white blood cell count and fibrinogen level) were evaluated at the baseline and before EC. The endpoint of this study was electrocardiographically confirmed recurrence of AF of &gt;10 min. &lt;i&gt;Results:&lt;\/i&gt; There were no significant differences in baseline characteristics and lipid and inflammatory marker levels between the treatment and control groups. Total cholesterol and low-density lipoprotein levels were significantly decreased in patients taking atorvastatin for 2 months compared with baseline values (174 \u00b1 31 vs. 129 \u00b1 25 mg\/dl, p = 0.001, and 112 \u00b1 23 vs. 62 \u00b1 20 mg\/dl, p = 0.001, respectively), while no significant change occurred in control patients (168 \u00b1 26 vs. 182 \u00b1 29 mg\/dl, p = 0.07, and 99 \u00b1 18 vs. 108 \u00b1 26 mg\/dl, p = 0.1, respectively). At the end of the 2-month follow-up period, 9 patients (20.5%) experienced AF recurrence, and there was no significant difference in AF recurrence rate between the treatment and control groups (26 vs. 13%; p = 0.2). &lt;i&gt;Conclusion:&lt;\/i&gt; Atorvastatin therapy prior to EC does not prevent the recurrence of arrhythmia in patients with persistent AF who are receiving antiarrhythmic therapy.<\/jats:p>","DOI":"10.1159\/000327674","type":"journal-article","created":{"date-parts":[[2011,7,12]],"date-time":"2011-07-12T06:13:52Z","timestamp":1310451232000},"page":"464-469","source":"Crossref","is-referenced-by-count":13,"title":["Atorvastatin Given prior to Electrical Cardioversion Does Not Affect the Recurrence of Atrial Fibrillation in Patients with Persistent Atrial Fibrillation Who Are on Antiarrhythmic Therapy"],"prefix":"10.1159","volume":"20","author":[{"given":"Kenan","family":"Demir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilknur","family":"Can","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Koc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Akif","family":"Vatankulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim","family":"Ayhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Akilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpay","family":"Aribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Alihanoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent Behlul","family":"Altunkeser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2011,7,11]]},"reference":[{"doi-asserted-by":"publisher","key":"ref1","DOI":"10.1001%2Farchinte.147.9.1561"},{"doi-asserted-by":"publisher","key":"ref2","DOI":"10.1038%2F415219a"},{"doi-asserted-by":"publisher","key":"ref3","DOI":"10.2174%2F0929867043456241"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.1093%2Feurheartj%2Fehi645"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.1161%2F01.CIR.0000103131.70301.4F"},{"doi-asserted-by":"publisher","key":"ref6","DOI":"10.1016%2Fj.amjcard.2004.07.108"},{"doi-asserted-by":"publisher","key":"ref7","DOI":"10.1161%2Fhc4901.101760"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.1016%2Fj.amjcard.2003.08.023"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.1016%2Fj.amjcard.2003.08.040"},{"doi-asserted-by":"publisher","key":"ref10","DOI":"10.1016%2Fj.amjcard.2005.11.082"},{"doi-asserted-by":"publisher","key":"ref11","DOI":"10.1016%2Fj.amjcard.2003.12.009"},{"doi-asserted-by":"publisher","key":"ref12","DOI":"10.1056%2FNEJM199902113400607"},{"doi-asserted-by":"publisher","key":"ref13","DOI":"10.1016%2Fj.amjcard.2006.07.019"},{"doi-asserted-by":"publisher","key":"ref14","DOI":"10.1378%2Fchest.128.5.3421"},{"doi-asserted-by":"publisher","key":"ref15","DOI":"10.1016%2FS0002-9149%2800%2901516-2"},{"doi-asserted-by":"publisher","key":"ref16","DOI":"10.1161%2F01.CIR.0000033635.42612.88"},{"doi-asserted-by":"publisher","key":"ref17","DOI":"10.1016%2Fj.pharmthera.2006.12.002"},{"doi-asserted-by":"publisher","key":"ref18","DOI":"10.1016%2FS0735-1097%2803%2900498-4"},{"doi-asserted-by":"publisher","key":"ref19","DOI":"10.1016%2Fj.cardiores.2004.01.018"},{"doi-asserted-by":"publisher","key":"ref20","DOI":"10.1016%2Fj.ahj.2005.06.032"},{"doi-asserted-by":"publisher","key":"ref21","DOI":"10.1161%2FCIRCULATIONAHA.106.621763"},{"doi-asserted-by":"publisher","key":"ref22","DOI":"10.1056%2FNEJM200003303421302"},{"doi-asserted-by":"publisher","key":"ref23","DOI":"10.1136%2Fheart.84.3.251"}],"container-title":["Medical Principles and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/327674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/327674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:15:06Z","timestamp":1745435706000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000327674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,7,1]]},"published-print":{"date-parts":[[2011,7,12]]}},"URL":"https:\/\/doi.org\/10.1159\/000327674","archive":["Portico"],"relation":{},"ISSN":["1011-7571","1423-0151"],"issn-type":[{"type":"print","value":"1011-7571"},{"type":"electronic","value":"1423-0151"}],"subject":[],"published":{"date-parts":[[2011]]}}}